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Myeloproliferative neoplasms (MPNs) are a heterogeneous
group of chronic clonal diseases which are characterized by
the excessive production of mature cells of one or more of
the myeloid lineages. The three main MPN subtypes are very
different diseases of distinct clinical presentation, evolution,
and variable severity, ranging from mild (essential throm-
bocythemia (ET)) to moderate (polycythemia vera (PV)) or
severe (primary myelofibrosis (PMF)). Recent advances in
the biology of MPNs have greatly facilitated the molecular
diagnosis of MPNs, since a large majority of MPN patients
present with mutation in one of three genes: JAK2, CALR,
and,more rarely,MPL. However, important questions remain
regarding the role of these mutations in the pathogenesis of
MPNs. While it is established that mutations in theMPL and
JAK2 genes result in increased activation of the JAK2/STAT5,
STAT3, and STAT1 pathways and hypersensitivity of myeloid
progenitors to hematopoietic cytokines, the consequences
of CALR mutations are not fully understood. Moreover, the
reasons why patients present with ET, PV, or PMF when the
JAK2-V617F mutation is found in all subtypes of MPNs, and
the CALR andMPLmutations are present in ET as well as in
PMF, are still not elucidated.
It has long been known that MPN patients present
with elevated levels of numerous inflammatory cytokines in
blood and bone marrow. Over time several groups estab-
lished links between inflammatory cytokine levels and MPN
phenotype, clinical symptoms, and certain complications.
More recently, JAK inhibitors were shown to efficiently
decrease the production and signaling ofmajor inflammatory
cytokines, leading to significant reduction of spleen size and
other invalidating inflammation-linked clinical symptoms in
PMF patients while the JAK2-mutated MPN clone remained
unaffected, as assessed by quantification of the JAK2 mutant
allelic burden. Thus a better knowledge of the causes and
molecular mechanisms that underlie inflammation in MPNs
could improve understanding of the pathogenesis of MPNs
and the treatments proposed to MPN patients.
To help achieve this aim, we invited authors who could
shed light on the contribution of inflammation (cytokines
and other inflammation markers) to mutation acquisition,
clone proliferation, biological parameters, clinical presenta-
tion, disease evolution, and response to treatment in MPNs.
Major investigators in the field thus described, analyzed, and
summarized the biological and clinical findings accumulated
in regard to inflammation in MPNs. Our hope is that inte-
grating inflammation in MPN pathophysiology can provide
the rationale for novel therapeutic strategies for MPNs that
target inflammation in addition to the main mutations.
In the paper entitled “Circulating Cytokine Levels as
Markers of Inflammation in Philadelphia Negative Myelo-
proliferativeNeoplasms: Diagnostic and Prognostic Interest”,
J. Mondet et al. discuss the importance of cytokines in
the development of MPNs and, subsequently, the interest
of determining the circulating levels of cytokines at the
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time of diagnosis. This extensive review presents the current
knowledge on cytokine profiles in the different subtypes
of MPNs and the role of altered cytokine expression in
the pathogenesis of myelofibrosis. Phenotypic correlation,
prognostic value of inflammation cytokines in MPNs, and
the impact of JAK inhibitors on inflammation cytokine levels
are discussed.The authors conclude that circulating cytokines
levels could be useful diagnostic and prognostic markers in
MPNs. They suggest that cytokine assays could be useful in
monitoring treatment efficacy, since a significant cytokine
reduction could serve as an indirect marker for therapeutic
compliance and efficacy.
In their paper “Impact of Inflammation on Myeloprolif-
erative Neoplasm Symptom Development”, H. L. Geyer et
al. describe inflammation markers characteristic of MPNs,
the upstream sources stimulating their development, their
prevalence within the MPN population, and the role they
play in symptomdevelopment.Theypresent Patient Reported
Outcome (PRO) tools designed for evaluating the poten-
tial associations between symptoms and inflammation. The
authors report clear relationships between individual MPN
symptoms (fatigue, abdominal complaints, microvascular
symptoms, and constitutional symptoms) and inflammatory
cytokines (interleukin- (IL-) 1, IL-6, IL-8, and tumor necrosis
factor- (TNF-) 𝛼). Information is also provided on the role
symptoms paradoxically play in cytokine production, as in
the case of fatigue-driven sedentary lifestyles. H. L. Geyer
et al. conclude that increased attention should be paid to
how inflammation markers differ between MPN subtypes,
change with disease progression, and relate to transformation
and anticipate novel inflammation-targeting therapies high
potential for symptomatic benefit.
The paper of G. Hoermann et al., entitled “Cytokine Reg-
ulation of Microenvironmental Cells in Myeloproliferative
Neoplasms,” reviews the role of MPN-related oncogenes in
cytokine expression and release by neoplastic cells and the
modulation of microenvironmental cells by these cytokines.
The authors describe common as well as distinct pathogenic
mechanisms underlying the microenvironmental changes
observed in the bone marrow and other organs of MPN
patients. Targeting of the microenvironment and of related
cytokines (or their receptors) as an attempt to improve thera-
pies inMPNs is also discussed, as such therapiesmay enhance
the efficacy and overcome resistance to established tyrosine
kinase inhibitors treatment in MPN patients. For instance,
the VEGF/VEGFR, HGF/c-MET, and SDF-1/CXCR4 axes are
presented as potential targets inMPNs.The authors conclude
that increasing knowledge of the leukemic stem cell- (LSC-)
niche interactions will assist in the development of new
improved treatment approaches in MPN patients.
In the paper entitled “Inflammation as aKeystone of Bone
Marrow Stroma Alterations in Primary Myelofibrosis,” C.
Desterke et al. discuss bone marrow stroma alterations in
PMF, as evidenced by myelofibrosis, neoangiogenesis, and
osteosclerosis, and the involvement of altered stromal cells in
PMF pathogenesis. The authors propose that the stroma may
be inflammatory-imprinted in vivo by clonal hematopoietic
cells and then becomes “independent” of hematopoietic cell
stimulation, rendering this inflammatory loop unbreakable
without the association of stroma-targeted therapies to the
current protocols.
M. E. Bjørn and H. C. Hasselbalch in “The Role of Reac-
tiveOxygen Species inMyelofibrosis and RelatedNeoplasms”
describe how reactive oxygen species (ROS) are involved
in MPN disease initiation and progression throughout the
biological continuum from early cancer stage (ET/PV) to
advanced cancer stage (myelofibrosis, or MF). Excess ROS,
oxidative stress, as a result of chronic inflammation with
consequent double stranded DNA breaks in combination
with a germline predisposition with impaired DNA repair
might account for genetic susceptibility in a subset of indi-
viduals implying an increased risk of acquiring an MPN
when suffering from chronic inflammatory diseases. The
authors hypothesize that the excess production of ROS, by
the malignant clone itself, in addition to carcinogenesis also
provides an escape from innate and adaptive tumor-immune-
surveillance, mainly by blocking interferon signaling. How
targeting of ROS with N-Acetyl-Cysteine (NAC) has been
a success in other inflammation-driven diseases and why
NAC-treatment should be pursued in MPNs as well are
discussed. Furthermore, the systemic excess production of
ROS also provides a link between the MPNs and MPN-
associated comorbidities, in particular the cardiovascular
disease-burden.
The paper of J. S. Jutzi and H. L. Pahl, with its provocative
title “The Hen or the Egg: Inflammatory Aspects of Murine
MPN Models,” addresses the contribution of inflammation
and other changes in the bone marrow niche in the genesis
and maintenance of MPNs. They compare data obtained in
gastrointestinal tumors with observations in MPN patients
andmodels and describe novelmurineMPNmodels thatmay
be used to address fundamental questions regarding the role
of inflammation in the pathogenesis of MPNs.
In the paper entitled “MPNs as Inflammatory Diseases:
The Evidence, Consequences, and Perspectives,” H. C. Has-
selbalch and M. E. Bjørn describe the evidence for con-
sidering the MPNs as inflammatory diseases, “A Human
Inflammation Model of Cancer Development,” and the role
of cytokines in disease initiation and progression.The conse-
quences of this model are discussed, including the increased
risk of second cancers and other inflammation-mediated
diseases, emphasizing the urgent need for rethinking our
therapeutic approach. Early intervention with interferon-
alpha 2, which as monotherapy has been shown to induce
minimal residual disease in a subset of PV patients, in
combination with potent anti-inflammatory agents such as
JAK-inhibitors and statins is foreseen as the most promising
new treatment modality in the years to come.
The paper of S. Hermouet et al. titled “Pathogenesis
of Myeloproliferative Neoplasms: Role and Mechanisms of
Chronic Inflammation” discusses the role played by the
JAK2, CALR, and MPL mutations in the pathogenesis of the
different subtypes of MPNs. The authors review the different
aspects of inflammation inMPNs, themainmolecular mech-
anisms involved, and the role of specific somatic or germline
genetic defects in the production of inflammatory cytokines.
They present evidence that certain inflammatory cytokines
present in excess in MPNs are produced independently
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from the JAK2-V617F mutation. The authors also discuss
several inflammation markers that have been identified in
MPNs as predictive markers independently of the JAK2-
V617F mutation and drugs that already exist and target these
markers. They also describe possible nongenetic causes of
inflammation.
A. G. Fleischman, in her paper “Inflammation as a Driver
of Clonal Evolution in Myeloproliferative Neoplasm,” pro-
vides evidence that the impact of chronic inflammation goes
far beyond its role as a driver of constitutional symptoms.The
author shows that inflammatory response to the neoplastic
clone may be responsible for different pathologic aspects
of MPNs and that the JAK2V617F-mutated progenitor cells
are resistant to the suppressive action of certain inflamma-
tory cytokines, which gives the neoplastic clone a selective
advantage and justifies targeting inflammation as a logical
therapeutic approach in MPNs.
Last but not least, M. Sevin et al. in “HSP90 and HSP70:
Implication in Inflammation Processes and Therapeutic
Approaches for Myeloproliferative Neoplasms” report that
heat shock proteins (HSP) are key players during inflam-
mation, through their chaperone activity. Notably, HSP90
stabilizes many oncogenes including JAK2 and also key
components of theNuclear Factor-kappaB (NF-𝜅B) signaling
pathway, which plays critical roles in the inflammatory
response. HSP70 represents another HSP to consider since
it tightly regulates the NF-𝜅B pathways. As expected, several
HSP90 inhibitors generated as anticancer agents allow the
degradation of oncogenes and inhibit the inflammatory
response. M. Sevin et al. also discuss the emergence of HSP
inhibitors in newprotocols designed for the therapy ofMPNs.
Altogether, the present special issue highlights the differ-
ent aspects and the importance of the contribution of inflam-
mation cytokines as crucial regulators of the MPN clone
and as mediators of clinical symptoms and complications.
The special issue also describes the effects of current drugs
or combinations of drugs acting on inflammation in MPNs
and proposes new lines of research and novel therapeutic
strategies targeting inflammation in MPNs.
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